U.S. Pharmaceuticals & Biotech Most Popular Stocks

Inhibikase Therapeutics

Market Cap: US$115.5m

Operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders.

Instil Bio

Market Cap: US$112.4m

A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.

Sera Prognostics

Market Cap: US$112.3m

A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.

Fate Therapeutics

Market Cap: US$112.0m

A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

Fortress Biotech

Market Cap: US$111.6m

A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.

Skye Bioscience

Market Cap: US$111.6m

A clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.

Cognition Therapeutics

Market Cap: US$111.2m

A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Anixa Biosciences

Market Cap: US$111.1m

A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

Spero Therapeutics

Market Cap: US$109.2m

A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Opus Genetics

Market Cap: US$108.4m

A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).

Armata Pharmaceuticals

Market Cap: US$108.0m

Operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Zentalis Pharmaceuticals

Market Cap: US$107.5m

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.

Atossa Therapeutics

Market Cap: US$105.5m

Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

Entasis Therapeutics Holdings

Market Cap: US$104.8m

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States.

MacroGenics

Market Cap: US$104.3m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

IO Biotech

Market Cap: US$104.1m

A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.

Nautilus Biotechnology

Market Cap: US$103.8m

A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

Vistagen Therapeutics

Market Cap: US$103.4m

A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.

Alto Neuroscience

Market Cap: US$102.9m

Operates as a clinical-stage biopharmaceutical company in the United States.

Surrozen

Market Cap: US$102.2m

A biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.

Pelthos Therapeutics

Market Cap: US$101.1m

A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

TScan Therapeutics

Market Cap: US$101.0m

A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

Ovid Therapeutics

Market Cap: US$100.3m

A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.

Anebulo Pharmaceuticals

Market Cap: US$100.2m

A clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.

Oramed Pharmaceuticals

Market Cap: US$98.4m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Burning Rock Biotech

Market Cap: US$98.1m

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.

Atara Biotherapeutics

Market Cap: US$97.1m

Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.

ALX Oncology Holdings

Market Cap: US$95.9m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

Adagene

Market Cap: US$95.2m

A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.

Nuo Therapeutics

Market Cap: US$94.8m

Operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States.

Connect Biopharma Holdings

Market Cap: US$94.2m

A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.

Insight Molecular Diagnostics

Market Cap: US$93.3m

Operates as a precision diagnostics company in the United States and internationally.

Werewolf Therapeutics

Market Cap: US$92.4m

A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.

Adverum Biotechnologies

Market Cap: US$90.4m

A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.

Acumen Pharmaceuticals

Market Cap: US$89.6m

A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.

Kalaris Therapeutics

Market Cap: US$89.2m

A clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.